Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ursela Baber"'
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
With unclear characteristics of post-infection and post-vaccination immunity, the multiple sclerosis community lacks evidence to guide patients on their continued coronavirus disease 2019 (COVID-19) infection risk. As disease modifying treatments all
Externí odkaz:
https://doaj.org/article/0e39d71420b3452ba6a20ad64049c928
Publikováno v:
Frontiers in neurology. 13
With unclear characteristics of post-infection and post-vaccination immunity, the multiple sclerosis community lacks evidence to guide patients on their continued coronavirus disease 2019 (COVID-19) infection risk. As disease modifying treatments all
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::789d3ee1cdcb8d06d1878c687e653b9f
https://pubmed.ncbi.nlm.nih.gov/35280260
https://pubmed.ncbi.nlm.nih.gov/35280260
Publikováno v:
Int J MS Care
Background: Patients with a compromised immune system are at risk for converting from latent tuberculosis infection (LTBI) to active tuberculosis (TB) infection. Multiple sclerosis (MS) therapies may put individuals with LTBI at higher risk of TB. Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ff3fd9b611fd78c3d932643f7c7ca0b
https://pubmed.ncbi.nlm.nih.gov/33658903
https://pubmed.ncbi.nlm.nih.gov/33658903
Publikováno v:
Multiple Sclerosis Journal-Experimental, Translational and Clinical
Background Studies linking MRI findings in MS patients with obstructive sleep apnea severity are limited. Objective We conducted a retrospective study to assess MRI abnormalities associated with obstructive sleep apnea (OSA) in patients with multiple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ff99bdd46e06637286d77c74951b381
http://europepmc.org/articles/PMC7649856
http://europepmc.org/articles/PMC7649856
Publikováno v:
Journal of neurology. 265(10)
Rituximab, a monoclonal antibody to CD20, is an effective treatment for relapsing remitting multiple sclerosis (MS) reducing relapse rate by at least 50% over time. Although the mechanism for this clinical benefit is unclear, rituximab depletes circu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6149fa88397aae71cd62d0ee1545b8da
https://pubmed.ncbi.nlm.nih.gov/30109480
https://pubmed.ncbi.nlm.nih.gov/30109480